Introduction {#s1}
============

Migraine is the third most prevalent and second most disabling neurological disease ([@B9]; [@B7]; [@B8]), with a lifetime prevalence of 33% in women and 13% in men ([@B34]). Occurring most frequently between the ages of 25 and 50 years, migraine is associated with a series of neurological and systemic symptoms. Indeed, the condition is characterized by recurrent moderate-to-severe headache accompanied by photophobia, phonophobia, cutaneous allodynia, and nausea. The headache attacks last from 4 to 72 h, and the average frequency of attacks is typically one or two times per month ([@B22]). Approximately 11% of adults worldwide experience migraine attacks, which significantly impact both quality of life and productivity ([@B2]). Currently, acute migraine treatments are largely abortive in nature. Migraine is primarily treated using triptans and/or nonsteroidal anti-inflammatory drugs (NSAIDs), although central analgesics may be used in some cases. However, when binding to effective receptors, triptans may also cause vasoconstriction of the cranial blood vessels and are thus contraindicated in patients with vascular diseases ([@B30]; [@B26]). Furthermore, because NSAIDs exert nonspecific anti-inflammatory effects that can alter gastrointestinal and renal function, they are not indicated for long-term use.

Calcitonin gene-related peptide (CGRP) is a member of the calcitonin family of peptides that is produced in both peripheral and central neurons. After CGRP is generated, it is captured by CGRP receptor and forms a complex. Also, the receptor complex functions by the G protein-coupled receptor calcitonin receptor-like receptor, and receptor activity-modifying protein 1 to mediate signal transduction and active adenylyl cyclise and cyclic adenosine monophosphate-dependent pathways, which results in level change of cyclic adenosine monophosphate active protein kinase A and phosphorylation of several downstream targets, dilate the blood vessel and helping to transmit pain signals ([@B27]; [@B23]; [@B12]). Previous research has also indicated that levels of CGRP increase during migraine attacks ([@B10]; [@B31]). Given the role of CGRP in migraine, several research groups have aimed to determine the clinical potential of CGRP receptor antagonists. However, research related to several such agents has been halted because of concerns regarding hepatotoxicity. Therefore, in the present study, we aimed to review the potential value of several CGRP receptor antagonists in the acute treatment of migraine.

Methods {#s2}
=======

Literature Search Strategy {#s2_1}
--------------------------

We systematically searched electronic databases, including PubMed, Embase, Ovid MEDLINE, Web of Science, and the Cochrane Central Register of Controlled Trials, for relevant studies published in English through October 2018. The following search terms were used: acute treatment, migraine, headache, calcitonin gene-related peptide, calcitonin gene-related peptide receptor antagonists, CGRP-receptorantagonists, telcagepant, olcegepant, BI 44370, rimegepant (BMS-927711), MK3207, ubrogepant, and randomized clinical trials.

The reference lists of included articles were also manually reviewed for other potentially eligible trials. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the PRISMA Extension were used for reference.

Study Eligibility {#s2_2}
-----------------

The following inclusion criteria were used to determine study eligibility: 1) Randomized controlled trials (RCTs) involving adult patients with migraine, patients' number with at least 10; 2) acute treatment with CGRP receptor antagonists, with at least one reported outcome measure \[pain-free at 2 h, adverse events (AEs), and drug-related AEs\]; 3) publication in English; 4) inclusion of a placebo or control arm; 5) with interesting results. When there were multiple publications associated with a single trial, we included only the most recent version. Updated data were regarded as new evidence. Two investigators (FX and WS) independently determined whether each study met the inclusion criteria, and all disagreements were resolved *via* consensus.

Data Extraction and Outcome Measures {#s2_3}
------------------------------------

Basic information was extracted by two investigators (FX and WS). Two-hour pain-free rate was regarded as the primary outcome measure. The toxicity and tolerability of each treatment were assessed based on AEs and drug-related AEs.

Risk of Bias {#s2_4}
------------

The risk of bias for each study was evaluated using the Cochrane risk of bias tool ([@B14]). This tool allows for the assessment of sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting for each RCT. Included RCTs were categorized as follows based on the risk of bias: low, high, or unclear.

Statistical Analysis {#s2_5}
--------------------

Network meta-analysis (NMA) is a method that combines direct and indirect evidence and synthesis data obtained *via* direct or indirect comparisons of different treatments and allow for inferences regarding the comparative effects of interventions without direct comparators. NMA can thus provide better comparative evidence than pair-wise meta-analysis. Because no previous RCTs have directly compared the effects of different CGRP receptor antagonists among patients with migraine, we adopted a Bayesian framework using the Markov chain Monte Carlo method. The network was constructed by comparing the following six major drugs: telcagepant, olcegepant, BI 44370, rimegepant (BMS-927711), MK3207, and ubrogepant. The comparative efficacy and toxicity of each treatment (i.e., 2-h pain-free rate and AE rate) was summarized using odds ratios (ORs) and the corresponding 95% credible intervals, the Bayesian equivalent of 95% confidence intervals (CIs). The inconsistency of the NMA was evaluated to determine the conformity between direct and indirect sources of evidence. The NMA yielded a ranking probability curve, which estimates the probability of each treatment to achieve the best rank among all treatments. When a treatment is certain to be the best, the surface under the cumulative ranking (SUCRA) value equals one (or 100%). Conversely, when a treatment is certain to be the worst, the SUCRA line equals zero (or 0%) ([@B29]; [@B1]).

All statistical tests were two-sided; *P* ≤ 0.05 was with statistical significance.

Statistical analyses were performed using the mvmeta command in Stata version 11.2 (StataCorp, College Station, TX, USA) ([@B1]). Mvmeta conducts meta-analysis of random multivariate effects and meta-regression of random multivariate effects on a data set of estimates, variances, and (optionally) covariances. The risk of bias was assessed using the Cochrane tool in Review Manager (RevMan, version 5.3, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).

Results {#s3}
=======

We identified a total of 516 relevant references based on a review of titles and abstracts. After excluding 216 duplicates and 283 articles not meeting the inclusion criteria (eight with non-English; 25 were not human researches; 121 were reviews; 23 were not finished; 67 with no interesting results; 39 were not target drugs), 17 trials remained. Among these, two were excluded due to the lack of control group, two were excluded due to study with no appropriate control group, two were excluded due to patients limited to certain conditions (e.g. coronary artery disease), and one was excluded due to a focus on migraine prevention. Thus, 10 RCTs met the eligibility criteria for our study. A total of 8,174 patients were included in the NMA. [**Figure 1**](#f1){ref-type="fig"} shows the procedures for the literature search and selection of clinical trials. The characteristics of the 10 included trials are summarized in [**Table 1**](#T1){ref-type="table"} ([@B28]; [@B19]; [@B17]; [@B4]; [@B15]; [@B3]; [@B5]; [@B13]; [@B24]; [@B33]).

![Diagram of eligible studies selection procedures.](fphar-10-00795-g001){#f1}

###### 

Baseline characteristics of involved patients.

  First author year   Drugs         No. of patients   Age    Male sex   Prior therapy   Aura   Moderate--severe headache                                                                          
  ------------------- ------------- ----------------- ------ ---------- --------------- ------ --------------------------- ---- ----- ----- ----- ----- ----- ----- ----- ---- ----- ---- ------- -----
  ([@B28])            Olcegepant    Placebo           85     41         47              47     14                          12   NA    NA    NA    NA    NA    NA    NA    NA   10    5    4       2
  ([@B19])            Telcagepant   Placebo           181    115        41.2            42.2   21                          11   61    40    70    35    23    24    26    13   45    13   181     115
                      Telcagepant   Rizatriptan       181    34         41.2            40.2   21                          6    61    8     70    16    23    4     26    5    45    8    181     34
  ([@B17])            Telcagepant   Placebo           687    348        42.6            42.3   110                         54   166   99    312   148   129   66    63    31   114   67   685     345
                      Telcagepant   Zolmitriptan      687    345        42.6            41.7   110                         47   166   86    312   154   129   63    63    34   114   63   685     343
  ([@B4])             Telcagepant   Placebo           929    365        41.6            41.9   124                         47   254   96    395   166   152   56    117   39   222   82   365     929
  ([@B15])            Telcagepant   Placebo           1122   555        43              42.5   161                         92   289   128   490   240   203   110   117   66   164   89   1,117   551
  ([@B5])             BI 44370 TA   Placebo           202    70         41.6            38.2   40                          9    NA    NA    NA    NA    NA    NA    NA    NA   NA    NA   199     70
                      BI 44370 TA   Eletriptan        202    69         41.6            37.9   40                          8    NA    NA    NA    NA    NA    NA    NA    NA   NA    NA   199     68
  ([@B3])             Telcagepant   Rizatriptan       641    313        42.5            41.9   139                         76   219   96    253   117   98    62    57    29   NA    NA   641     313
  ([@B13])            MK-3207       Placebo           407    140        42.8            42.1   56                          15   NA    NA    326   117   NA    NA    NA    NA   NA    30   407     140
  ([@B24])            Rimegepant    Placebo           547    229        39.6            37.9   98                          33   NA    NA    NA    NA    NA    NA    NA    NA   NA    NA   547     229
                      Rimegepant    Sumatriptan       547    109        39.6            40.6   98                          18   NA    NA    NA    NA    NA    NA    NA    NA   NA    NA   547     109
  ([@B33])            Ubrogepant    Placebo           527    113        40.9            40.5   67                          15   376   82    216   44    NA    NA    111   26   NA    NA   527     113

NA, not available; T, treatment group; C, control group; NSAIDs, nonsteroidal anti-inflammatory drugs; NO, number.

Four trials included three arms involving 2,936 patients, while the others included two arms involving 5,238 patients. Four trials were in phase III, while the remaining six were in phase II. Five trials investigated telcagepant treatment, while olcegepant, BI 44370, MK-3207, rimegepant, and ubrogepant treatments were investigated in one trial each. The strategies adopted in each study are presented in [**Table 2**](#T2){ref-type="table"}.

###### 

Characteristics of trials.

  -------------------------------------------------------------------------------------------------------
  Study      Phase   Regimens                              Blinding                        
  ---------- ------- ------------------------------------- ------------------------------- --------------
  ([@B28])   2       0.1, 0.25, 0.5, 1, 2.5, 5, 10 mg\     Placebo                         Double-blind
                     Olcegepant                                                            

  ([@B19])   2       25, 50, 100, 200, 300, 400, 600 mg\   10 mg Rizatriptan or placebo    Double-blind
                     Telcagepant (MK-0974)                                                 

  ([@B17])   3       150 mg, 300 mg Telcagepant            5 mg Zolmitriptan or placebo    Double-blind

  ([@B4])    2       50, 150, 300 mg Telcagepant           Placebo                         Double-blind

  ([@B15])   3       140 mg, 280 mg Telcagepant            Placebo                         Double-blind

  ([@B3])    3       300 mg, 280 mg Telcagepant            10 mg Rizatriptan               Double-blind

  ([@B5])    2       50, 200, 400 mg BI 44370 TA           40 mg Eletriptan or placebo     Double-blind

  ([@B13])   2       2.5, 5, 10, 20, 50, 100, 200 mg\      Placebo                         Double-blind
                     MK-3207                                                               

  ([@B24])   2       10, 25, 75, 150, 300, 600 mg\         100 mg Sumatriptan or placebo   Double-blind
                     Rimegepant (BMS-927711)                                               

  ([@B33])   2       1, 10, 25, 50, 100 mg Ubrogepant      Placebo                         Double-blind
  -------------------------------------------------------------------------------------------------------

Efficacy {#s3_1}
--------

The efficacy of each drug was evaluated on the basis of the 2-h pain-free rate. Nine comparisons across 10 trials were included in network plot ([**Figure 2**](#f2){ref-type="fig"}). The NMA revealed that olcegepant (OR: 4.09; CI: 1.81, 9.25), ubrogepant (OR: 2.11; CI: 1.10, 4.05), and BI 44370 (OR: 3.36; CI: 2.24, 5.04) were more effective than placebo treatment. Furthermore, olcegepant treatment was superior to the other five treatments, although these differences were not statistically significant ([**Figure 3**](#f3){ref-type="fig"}). Our results also indicated that triptans were marginally less effective than olcegepant treatment, based on the 2-h pain-free rate (OR: 0.82; CI: 0.33, 2.04). SUCRA analysis indicated that olcegepant was most likely to be the best treatment (SUCRA: 0.84; PrBest: 53.3%), followed by triptans (SUCRA: 0.78; PrBest: 20.7%) and MK-3207 (SUCRA: 0.55; PrBest: 4.1%) ([**Table S1**](#SM3){ref-type="supplementary-material"}).

![Network plot for 2-h pain-free of six different calcitonin gene-related peptide (CGRP) antagonists. Lines represent direct comparisons within the randomized controlled trials (RCTs). The line thickness indicates the number of RCTs included in each comparison.](fphar-10-00795-g002){#f2}

![Efficacy analysis results for 2-h pain-free of six treatment modalities. OR, odds ratio; CI, confidence interval; PrI, predictive interval; O, olcegepant; Te, telcagepant; Tr, triptan; M, MK3207; Bm, rimegepant (BMS-927711); U, ubrogepant; Bi, BI 44370; P, placebo.](fphar-10-00795-g003){#f3}

Safety and Toxicity {#s3_2}
-------------------

Safety and toxicity were evaluated on the basis of AEs and drug-related AEs. There were no significant differences in AEs among telcagepant, olcegepant, MK-3207, and rimegepant. BI 44370 was associated with an increased risk of AEs (OR: 1.57; CI: 1.32, 1.88), and ubrogepant was even with lower risk of AEs (OR: 0.77; CI: 0.61, 0.96) when compared with placebo treatment ([**Figure 4**](#f4){ref-type="fig"}). The SUCRA analysis suggested that ubrogepant was associated with the lowest risk of AEs (SUCRA: 0.73) ([**Table S1**](#SM3){ref-type="supplementary-material"}). There were no significant differences in drug-related AEs among the six treatments ([**Figure 5**](#f5){ref-type="fig"}).

![Adverse events analysis of six treatment modalities. OR, odds ratio; CI, confidence interval; PrI, predictive interval; O, olcegepant; Te, telcagepant; Tr, triptan; M, MK3207; Bm, rimegepant (BMS-927711); U, ubrogepant; Bi, BI 44370; P, placebo.](fphar-10-00795-g004){#f4}

![Drug-related adverse events analysis of six treatment modalities. OR, odds ratio; CI, confidence interval; PrI, predictive interval; O, olcegepant; Te, telcagepant; Tr, triptan; M, MK3207; Bm, rimegepant (BMS-927711); P, placebo.](fphar-10-00795-g005){#f5}

Rank Analysis {#s3_3}
-------------

A combined ranking plot was used to evaluate both efficacy (2-h pain-free rate) and toxicity (AEs) ([**Figure 6**](#f6){ref-type="fig"}). The ideal treatment option should appear in the upper right corner (i.e., higher efficacy and acceptability, acceptability is equal to low toxicity). Our analysis indicated that olcegepant was more effective than the remaining treatments, including triptans. Although toxicity values were lower for the other five treatments than for olcegepant, these treatments were associated with lower efficacy.

![Rank results for efficacy and acceptability (low toxicity).](fphar-10-00795-g006){#f6}

Assessment of Heterogeneity and Inconsistency {#s3_4}
---------------------------------------------

There was no heterogeneity in the NMA for 2-h pain-free rate and AEs (tau-square = 0, *I* ^2^ = 0.0%). However, drug-related AEs (tau-square = 0.105, *I* ^2^ = 55.5%) exhibited heterogeneity, as shown in [**Supplementary Table S1**](#SM3){ref-type="supplementary-material"}. Although inconsistency was observed in the meta-analysis of AEs (*P* = 0.02), it was not observed in the networks for other indices ([**Table S2**](#SM4){ref-type="supplementary-material"}). We did not perform meta-regression analyses to explore sources of inconsistency due to the limited amount of existing data for direct treatment comparisons.

Risk of Bias {#s3_5}
------------

We examined all articles using the Cochrane risk of bias tool. Our analysis indicated that most trials were of low risk, as shown in [**Figures S1**](#SM1){ref-type="supplementary-material"} and [**S2**](#SM2){ref-type="supplementary-material"}.

Discussion {#s4}
==========

CGRP is a potent neurotransmitter in the central nervous system, and recent studies have highlighted the potential of CGRP receptor blockade in the acute treatment of migraine. However, most studies have only investigated the clinical efficacy of individual agents relative to placebo treatment, rather than the efficacy of different CGRP antagonists in relation to one another. Thus, in the present study, we examined the efficacy and toxicity of six major CGRP antagonists.

Among the six major treatments investigated in our NMA (olcegepant, MK3207, BI 44370, telcagepant, ubrogepant, and rimegepant), olcegepant exhibited the greatest efficacy, based on the 2-h pain-free rate in patients with migraine. Furthermore, olcegepant was superior to triptans in the rank analysis, which considered both efficacy and toxicity. We also observed that MK3207 and rimegepant were associated with moderate efficacy and moderate toxicity, while ubrogepant, telcagepant, and BI 44370 were associated with moderate efficacy and low toxicity. In addition, our results indicated that olcegepant, MK3207, BI 44370, telcagepant, ubrogepant, and rimegepant were associated with lower toxicity than triptans. Previous meta-analysis study evaluated the efficacy of CGRP antagonists in acute treatment of migraine compared with that of triptans ([@B21]), and CGRP antagonists was as one class of drug. In current study, we separated CGRP antagonists as individual comparisons (e.g. olcegepant, MK3207, BI44370, telcagepant, ubrogepant, and rimegepant). This enabled us to analyze the effect of each kind of CGRP antagonists for the acute treatment of migraine.

There several advantages in this study. It is the first NMA to compare different CGRP antagonists in the acute treatment of migraine, analyzing the effect of single drug in treatment and providing new clinical insight. Secondly, in rank analysis, we integrate the data of drug effects and adverse rates together for making assessments thoroughly, meanwhile, make the illustration within one graph to interpret clearly.

Although our results indicated that olcegepant was the most effective of the six treatments investigated, research regarding olcegepant has been discontinued due to its high molecular weight and limited ability to penetrate the brain ([@B11]; [@B20]). In addition, although telcagepant and BI 44370 were associated with moderate efficacy and low toxicity in acute intermittent treatment, research regarding these compounds has been discontinued due to hepatotoxicity concerns during long-term prophylactic use ([@B3]; [@B5]). However, prolonged intermittent use of telcagepant results in only transient increases in liver aminotransferase, and there is no evidence to suggest that telcagepant alters liver function ([@B16]; [@B18]). Research regarding MK3207, which exhibited moderate efficacy and moderate toxicity in our study, has also been suspended due to concerns regarding hepatotoxicity. However, ongoing studies are investigating the clinical potential of ubrogepant (moderate efficacy, low toxicity) and rimegepant (moderate efficacy, moderate toxicity), the latter of which exerts minimal effects on liver transaminases.

Triptans represent the first-line treatment for acute migraine. However, because triptans bind both the receptors located on peripheral trigeminal sensory nerve endings and those located on intracranial, extracranial, and systemic blood vessels ([@B6]; [@B25]), the mechanisms underlying their efficacy can also cause vasoconstriction. Thus, triptans are not suitable for patients with vascular risk factors. Moreover, research has indicated that approximately 30 to 40% of patients do not respond adequately to triptan therapy ([@B32]). Thus, it is necessary to identify alternative treatment strategies for patients with migraine. CGRP antagonists have been promising in recent studies, especially with regard to AEs, as these drugs exhibit toxicity levels lower than or similar to those of triptans. Studying these drugs, whether discontinued or not, is of utmost importance for current and future drug discovery.

Limitations {#s4_1}
-----------

Our study has several limitations to note. First, although all eligible trials had similar inclusion criteria, some differences were unavoidable, such as slight differences in patient characteristics (e.g., the presence or absence of aura, variations in previous drug treatment, etc.). Although these factors may have influenced our results, we did not perform subgroup analyses because of a lack of relevant information. Second, as research regarding some drugs has been suspended, data on olcegepant, MK3207, BI 44370, ubrogepant, and rimegepant were limited. Given that only one trial investigated each of these agents, our results should be interpreted with caution.

Conclusion {#s5}
==========

Olcegepant was more effective and ubrogepant had lower toxicity than the remaining treatments. CGRP antagonists are promising for the acute treatment of migraine, especially among patients who cannot take triptans or who have not responded to triptan treatment. Further studies regarding ubrogepant and rimegepant may dispel previous concerns regarding the hepatotoxicity of CGRP antagonists.
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